Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Truist Financial Analyst Says

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price boosted by investment analysts at Truist Financial from $264.00 to $281.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s target price points to a potential upside of 8.78% from the stock’s previous close.

Several other brokerages have also recently weighed in on JAZZ. Wells Fargo & Company lifted their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. boosted their price objective on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Piper Sandler increased their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. TD Cowen lifted their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $275.95.

Jazz Pharmaceuticals Stock Down 0.7%

NASDAQ:JAZZ traded down $1.91 during mid-day trading on Wednesday, reaching $258.32. The company’s stock had a trading volume of 508,070 shares, compared to its average volume of 929,000. The stock has a fifty day moving average of $245.93 and a 200-day moving average of $216.92. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $16.77 billion, a PE ratio of 17.79, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32. Jazz Pharmaceuticals has a 1 year low of $123.87 and a 1 year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company’s revenue was up 15.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($8.25) earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals will post 21.66 earnings per share for the current year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total value of $1,517,880.00. Following the completion of the transaction, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the sale, the executive vice president owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 14,357 shares of company stock worth $3,505,642. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Allianz Asset Management GmbH raised its position in shares of Jazz Pharmaceuticals by 68.2% during the 4th quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after acquiring an additional 242,892 shares in the last quarter. Castleark Management LLC acquired a new stake in Jazz Pharmaceuticals in the first quarter worth approximately $9,214,000. SEB Asset Management AB bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $8,765,000. Swedbank AB lifted its stake in Jazz Pharmaceuticals by 2.7% during the fourth quarter. Swedbank AB now owns 1,102,974 shares of the specialty pharmaceutical company’s stock valued at $187,506,000 after buying an additional 28,882 shares in the last quarter. Finally, UBS Group AG boosted its position in Jazz Pharmaceuticals by 2.9% in the 4th quarter. UBS Group AG now owns 472,952 shares of the specialty pharmaceutical company’s stock valued at $80,402,000 after buying an additional 13,485 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Needham & Company raised its price target for JAZZ from $292 to $310 and reaffirmed a “Buy” rating, implying approximately 19% upside from the referenced share price. The upgrade reflects confidence in Jazz’s growth outlook. Benzinga
• Positive Sentiment: The FDA approved two Ziihera (zanidatamab-hrii) regimens for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. The broader label allows Ziihera with tislelizumab and chemotherapy for eligible patients regardless of PD-L1 status, potentially expanding the addressable market and establishing a new standard of care. FDA approval announcement
• Positive Sentiment: Coverage of the approval suggests Ziihera could become a blockbuster product, giving Jazz a potentially important commercial growth driver beyond its existing portfolio. Ziihera sales outlook
• Neutral Sentiment: Brokerages maintain an overall “Buy” recommendation for Jazz, reinforcing generally favorable Wall Street sentiment but providing limited incremental information beyond the Needham target increase. Brokerage recommendation
• Negative Sentiment: Jazz announced plans to issue $1.0 billion of exchangeable senior notes due 2032, with an option for up to an additional $150 million, while also repurchasing ordinary shares. The buybacks may support per-share value, but the financing adds debt-like obligations and could create future dilution if the notes are exchanged. Exchangeable notes and share repurchases

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.